Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0414 | Verteporfin

Molecular Formula C41H42N4O8
Molecular Weight 718.8
Structure
State solid
Route of elimination Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.
Half life Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.
Trade names Visudyne
Description a benzoporphyrin derivative

S

S01LA01 Verteporfin


[S01LA] Antineovascularisation agents


[S01L] OCULAR VASCULAR DISORDER AGENTS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 3.27±1.85 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 8.69 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 21.83±7.79 rat hepatocytes MMP assay decrease IC50 163

  • Age-related macular degeneration

  • Choroidal neovascularisation

  • Histoplasmosis

    • (+-)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester mixture with (+-)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid (2R,21S)-2,21-Dihydro-8-vinyl-2,7,12,18-tetramethyl-17-[2-(methoxycarbonyl)ethyl]-21,22-bis(methoxycarbonyl)-21H,23H-benzo[b]porphyrin-13-propionic acid
    (2R,21S)-8-Ethenyl-2,21-dihydro-13-(3-hydroxy-3-oxopropyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-22H,24H-benzo[b]porphyrin-21,22-dicarboxylic acid dimethyl ester (4R,4aS)-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester (4S,4aR)-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid 9-methyl ester
    133513-12-9 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester 23H,25H-Benzo(b)porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, 9-monomethyl ester, trans-
    23H,25H-Benzo(b)porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans- 2C41H42N4O8 3-[(1Z,6Z,12Z,17Z,23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1(3,6).1(8,11).113,16.019,24]octacosa-1,3(28),4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic acid
    9-Methyl-trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoate,DL- AB01566862_01 AB2000292
    AOB5623 BPD verteporfin Bpd-ma(sub C)
    CHEBI:60775 CHEMBL2052016 CHEMBL3822934
    CL 318,952 CL-315555 DB00460
    DTXSID30892511 EX-A1344 J-005685
    J2.000.745A LS-172730 LS-187701
    NCGC00346712-01 NOCAS_892511 SCHEMBL14257223
    SCHEMBL6219 SW219955-1 UNII-0X9PA28K43 component YTZALCGQUPRCGW-MXVXOLGGSA-N
    UNII-WU713D62N9 component YTZALCGQUPRCGW-MXVXOLGGSA-N Verteporfin C5 isomer Verteporfin [USAN:INN]
    Verteporfin [USAN:USP:INN:BAN] Verteporfina Verteporfine
    Verteporfinum Visudyne s1786
    verteporfin (product), verteporfin (product), verteporfin (substance), verteporfin (substance), bpd-MA, bpd-MA, novartis brand of verteporfin, novartis brand of verteporfin verteporphin

    DrugBank Name Verteporfin
    DrugBank DB00460
    CAS Number 129497-78-5, 133513-12-9
    PubChem Compound 5362420
    KEGG Drug D01162
    PubChem.Substance 46506236
    ChEBI 32293
    PharmGKB PA451871
    ChemSpider 4515032
    Wikipedia Verteporfin
    DPD 11996